Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

By S. Champiat, L. Dercle, S. Ammari, C. Massard, A. Hollebecque, S. Postel-Vinay, N. Chaput, A. Eggermont, A. Marabelle, J. Soria and 1 more. Clinical Cancer Research, 2016

1,067 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f44acb172a9e3e4ca933b99bf9e2870d79e3f138

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (2019, background): “” Alternatively, other accepted definitions of hyperprogression found in the literature include: a “RECIST progression at the first evaluation and as a ≥2fold increase of the tumor growth rate between the reference and the experimental periods” [90], “time-to-”
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (2018, background): “of patients 240 759 Median age, years (range) 66 (22-92) 66 (22-93) .”
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations (2018, background): “In addition, one study was among the first to describe the existence of a subset of patients (9%) experiencing hyperprogressive disease defined as RECIST progression at first evaluation characterized by a ≥ 2-fold increase in tumor growth rate in response to anti-PD-1/PD-L1 therapy [70].”
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer (2019, background): “HPD was defined as previously reported (6): time-to-treatment failure <2 mo, >50% increase in tumor burden compared with pretreatment imaging, and >twofold increase in progression speed.”
Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate (2017, background): “Champiat and colleagues (9) demonstrated that 9% of patients (12/131) showed a 2fold increase in tumor burden when compared with preimmunotherapy imaging.”